New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
06:39 EDTACTActavis price target raised to $203 from $175 at Piper Jaffray
Piper Jaffray raised its price target for Actavis shares to $203 citing the depth of the company's pipeline and the potential for a merger deal. Piper reiterates an Overweight rating on the stock.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:12 EDTACTAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
April 28, 2015
17:00 EDTACTActavis, Medicines360 announce publication of ACCESS IUS study of LILETTA
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that the initial results of ACCESS IUS, or A Comprehensive Contraceptive Efficacy and Safety Study of an IUS, were published online today in the medical journal Contraception. The study found that LILETTA, or levonorgestrel-releasing intrauterine system, 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity, or body mass index. The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use.
10:19 EDTACTPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
April 24, 2015
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
07:09 EDTACTCipher Pharmaceuticals announces Markman hearing in Absorica patent suit
Subscribe for More Information
April 23, 2015
08:16 EDTACTActavis launches Avycaz anti-infective in U.S.
Subscribe for More Information
April 22, 2015
07:37 EDTACTOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 20, 2015
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use